Prescription stimulant use and hospitalization for psychosis or mania: A population-based study

Journal of Clinical Psychopharmacology

Volumn 35, Issue 6, 2015, Pages 667-671

  Cressman, Alex M ^a,b   Macdonald, Erin M ^a   Huang, Anjie ^a   Gomes, Tara ^a,c,d,e   Paterson, Michael J ^a,d   Kurdyak, Paul A ^a,b,f   Mamdani, Muhammad M ^a,c,d,e,g   Juurlink, David N ^a,b,c,d,h  

^a Institute for Clinical Evaluative Sciences   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h Canada   (Canada)

Author keywords

attention deficit hyperactivity disorder; drug safety; mania; psychosis; stimulants

Indexed keywords

AMPHETAMINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATOMOXETINE; BENZODIAZEPINE DERIVATIVE; CENTRAL STIMULANT AGENT; CORTICOSTEROID; INSULIN; METHYLPHENIDATE; NEUROLEPTIC AGENT; OPIATE; OSELTAMIVIR;

ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MOOD DISORDER; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SLEEP DISORDER; ADOLESCENT; BIPOLAR DISORDER; CHEMICALLY INDUCED; PSYCHOSES, SUBSTANCE-INDUCED; STANDARDS; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG PRESCRIPTIONS; FEMALE; HOSPITALIZATION; HUMANS; MALE; PSYCHOSES, SUBSTANCE-INDUCED; YOUNG ADULT;

EID: 84947031298     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000406     Document Type: Article

References (44)

1. Ilyas S, Moncrieff J. Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010. Br J Psychiatry. 2012;200:393-398.
2. Setlik J, Bond GR, Ho M. Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications. Pediatrics. 2009;124:875-880.
3. Visser SN, Danielson ML, Bitsko RH, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. J Am Acad Child Adolesc Psychiatry. 2014;53:34. e2-46. e2.
4. U. S. Drug Enforcement Administration, Office of Diversion Control. National Forensic Laboratory Information System Special Report: ADD/ADHD Stimulants in NFLIS, 2007-2011. Springfield, VA: U. S. Drug Enforcement Administration; 2012.
5. Arnsten AF. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology. 2006;31:2376-2383.
6. Charach A, Dashti B, Carson P, et al. Attention Deficit Hyperactivity Disorder: Effectiveness of Treatment in At-Risk Preschoolers; Long-Term Effectiveness in All Ages; and Variability in Prevalence, Diagnosis, and Treatment. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
7. Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry. 2007;46:989-1002.
8. Molina BS, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48:484-500.
9. Mosholder AD, Gelperin K, Hammad TA, et al. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics. 2009;123:611-616.
10. Rashid J, Mitelman S. Methylphenidate and somatic hallucinations. J Am Acad Child Adolesc Psychiatry. 2007;46:945-946.
11. Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry. 2006;163: 1149-1152.
12. Calello DP, Osterhoudt KC. Acute psychosis associated with therapeutic use of dextroamphetamine. Pediatrics. 2004;113:1466.
13. Cherland E, Fitzpatrick R. Psychotic side effects of psychostimulants: a 5-year review. Can J Psychiatry. 1999;44:811-813.
14. Ney PG. Psychosis in a child, associated with amphetamine administration. Can Med Assoc J. 1967;97:1026-1029.
15. Gelperin K, Phelan K. Psychiatric adverse events associated with drug treatment of ADHD: review of postmarketing safety data. US Food and Drug Administration. The DDRE ADHD Psychiatric Review Team. Division of Drug Risk Evaluation (DDRE). Office of Drug Safety (ODS) March 3, 2006. Report No: FDA Report PID D050243. Silver Spring, MD.
16. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133:144-153.
17. Peters A, von Klot S, Heier M, et al. Exposure to traffic and the onset of myocardial infarction. N Engl J Med. 2004;351:1721-1730.
18. Mittleman MA, Maclure M, Tofler GH, et al. Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. N Engl JMed. 1993;329:1677-1683.
19. Wang S, Linkletter C, Dore D, et al. Age, antipsychotics, and the risk of ischemic stroke in the Veterans Health Administration. Stroke. 2012; 43:28-31.
20. Sun Y, Wu CS, Olsen J. Trimethoprim use before pregnancy and risk of congenital malformation: reanalyzed using a case-crossover design and a case-time-control design. Pharmacoepidemiol Drug Saf. 2014;23: 1076-1083.
21. Lin ST, Chen CC, Tsang HY, et al. Association between antipsychotic use and risk of acute myocardial infarction: a nationwide case-crossover study. Circulation. 2014;130:235-243.
22. Levy AR, O'Brien BJ, Sellors C, et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10:67-71.
23. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl JMed. 2006;354: 1352-1361.
24. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. NEngl JMed. 2004;351:543-551.
25. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011;305:783-789.
26. Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007; 298:2634-2643.
27. Fralick M, Macdonald EM, Gomes T, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ. 2014;349:g6196.
28. JuurlinkDN, Gomes T, Lipscombe LL, et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ. 2009;339:b2942.
29. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.
30. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716-723.
31. Mayes SD, Calhoun SL, Bixler EO, et al. ADHD subtypes and comorbid anxiety, depression, and oppositional-defiant disorder: differences in sleep problems. J Pediatr Psychol. 2009;34:328-337.
32. Bond DJ, Hadjipavlou G, Lam RW, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry. 2012; 24:23-37.
33. Park S, Cho MJ, Chang SM, et al. Prevalence, correlates, and comorbidities of adult ADHD symptoms in Korea: results of the Korean epidemiologic catchment area study. Psychiatry Res. 2011; 186:378-383.
34. Nierenberg AA, Miyahara S, Spencer T, et al. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry. 2005;57:1467-1473.
35. Janowsky DS, Davis JM. Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms. Arch Gen Psychiatry. 1976;33:304-308.
36. Janowsky DS, el-YouselMK, Davis JM, et al. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry. 1973;28:185-191.
37. Larsson H, Ryden E, Boman M, et al. Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder. Br J Psychiatry. 2013;203:103-106.
38. Hamshere ML, Stergiakouli E, Langley K, et al. Shared polygenic contribution between childhood attention-deficit hyperactivity disorder and adult schizophrenia. Br J Psychiatry. 2013;203:107-111.
39. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013;381:1371-1379.
40. Dalsgaard S, Mortensen PB, Frydenberg M, et al. Association between attention-deficit hyperactivity disorder in childhood and schizophrenia later in adulthood. Eur Psychiatry. 2014;29:259-263.
41. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47:21-31.
42. MacCabe JH, Wicks S, Löfving S, et al. Decline in cognitive performance between ages 13 and 18 years and the risk for psychosis in adulthood: a Swedish longitudinal cohort study inmales. JAMA Psychiatry. 2013;70:261-270.
43. Nosarti C, Reichenberg A, Murray RM, et al. Preterm birth and psychiatric disorders in young adult life. Arch Gen Psychiatry. 2012;69:E1-E8.
44. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.